Interviewer: Dr. Jacob Lalezari,
thank you very much for
taking the time to connect with us today
to discuss CytoDyn's efforts in developing
a COVID-19 treatment.
Your lead molecule right now is
a monoclonal antibody called Leronlimab.
CytoDyn has been testing Leronlimab in
clinical trials for some years now for
What were those indications for
how well did this agent
fare in clinical trials?
Dr. Lalezari: First of all it's
a pleasure to be here today.
It's a very curious history with
Leronlimab, it has been developed and
been in the pipeline for HIV treatment
for, I think, about 15 years now,
and it's been handed off
to one group after another.
The mechanism of action is that it
is a monoclonal antibody which binds
to a T-cell receptor called CCR5, and
its activity in HIV is completely
separate from our more interesting and
recent work in COVID-19.
CCR5 is the T-cell receptor that HIV just
happens to use to get inside the T-cell.
It is there as a receptor that
mediates inflammation and
cell-trafficking in the immune system,
but it just happens to be the receptor
that is part of the three-step
sequence of HIV entry into T-cells.
It has an interesting history
because the plague bacillus (called
the bubonic plague back in 1347) also used
the CCR5 receptor to get inside T-cells,